Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer

E. Claire Dees, Karen P. McKinnon, Jennifer J. Kuhns, Kathryn A. Chwastiak, Scotty Sparks, Mary Myers, Edward J. Collins, Jeffrey A Frelinger, Henrik Van Deventer, Frances Collichio, Lisa A. Carey, Mark E. Brecher, Mark Graham, H. Shelton Earp, Jonathan S. Serody

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: Immunotherapy using either dendritic cells (DCs) or expanded cytotoxic T cells (CTLs) has received increased interest in the treatment of specific malignancies including metastatic breast cancer (MBC). DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated. Methods: We enrolled ten patients with MBC that had received prior chemotherapy for the treatment of metastatic disease on a phase I/II trial designed to test the safety and feasibility of administering ex vivo expanded DCs from CD34 + progenitor cells. Results: Using a cocktail of multiple different cytokines, we could expand DCs 19-fold compared to the initial CD34-selected product, which allowed the administration of as many as six vaccine treatments per patient. Patients received three to six injections i.v. of DCs pulsed with either the wild type GP2 epitope from the HER-2/neu protein or an altered peptide ligand, isoleucine to leucine (I2L). Toxicity was mild, with no patients demonstrating grade III toxicity during the treatment. Two patients with subcutaneous disease had a partial response to therapy, while IFN-γ-producing CD8+ T cells could be found in two other patients during treatment. Conclusions: This approach is safe and effective in generating a significant quantity of DCs from CD34-precursors.

Original languageEnglish (US)
Pages (from-to)777-785
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume53
Issue number9
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Dendritic Cells
Breast Neoplasms
Therapeutics
T-Lymphocytes
Drug Therapy
Isoleucine
Leucine
Immunotherapy
Epitopes
Monocytes
Stem Cells
Vaccines
Cytokines
Ligands
Safety
Peptides
Injections
Neoplasms
Proteins

Keywords

  • Altered peptide ligand
  • Dendritic cell
  • HER-2/neu
  • Immunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Dees, E. C., McKinnon, K. P., Kuhns, J. J., Chwastiak, K. A., Sparks, S., Myers, M., ... Serody, J. S. (2004). Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunology, Immunotherapy, 53(9), 777-785.

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. / Dees, E. Claire; McKinnon, Karen P.; Kuhns, Jennifer J.; Chwastiak, Kathryn A.; Sparks, Scotty; Myers, Mary; Collins, Edward J.; Frelinger, Jeffrey A; Van Deventer, Henrik; Collichio, Frances; Carey, Lisa A.; Brecher, Mark E.; Graham, Mark; Earp, H. Shelton; Serody, Jonathan S.

In: Cancer Immunology, Immunotherapy, Vol. 53, No. 9, 09.2004, p. 777-785.

Research output: Contribution to journalArticle

Dees, EC, McKinnon, KP, Kuhns, JJ, Chwastiak, KA, Sparks, S, Myers, M, Collins, EJ, Frelinger, JA, Van Deventer, H, Collichio, F, Carey, LA, Brecher, ME, Graham, M, Earp, HS & Serody, JS 2004, 'Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer', Cancer Immunology, Immunotherapy, vol. 53, no. 9, pp. 777-785.
Dees EC, McKinnon KP, Kuhns JJ, Chwastiak KA, Sparks S, Myers M et al. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunology, Immunotherapy. 2004 Sep;53(9):777-785.
Dees, E. Claire ; McKinnon, Karen P. ; Kuhns, Jennifer J. ; Chwastiak, Kathryn A. ; Sparks, Scotty ; Myers, Mary ; Collins, Edward J. ; Frelinger, Jeffrey A ; Van Deventer, Henrik ; Collichio, Frances ; Carey, Lisa A. ; Brecher, Mark E. ; Graham, Mark ; Earp, H. Shelton ; Serody, Jonathan S. / Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. In: Cancer Immunology, Immunotherapy. 2004 ; Vol. 53, No. 9. pp. 777-785.
@article{729f40153bdc480880b7a21700ef5bca,
title = "Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer",
abstract = "Purpose: Immunotherapy using either dendritic cells (DCs) or expanded cytotoxic T cells (CTLs) has received increased interest in the treatment of specific malignancies including metastatic breast cancer (MBC). DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated. Methods: We enrolled ten patients with MBC that had received prior chemotherapy for the treatment of metastatic disease on a phase I/II trial designed to test the safety and feasibility of administering ex vivo expanded DCs from CD34 + progenitor cells. Results: Using a cocktail of multiple different cytokines, we could expand DCs 19-fold compared to the initial CD34-selected product, which allowed the administration of as many as six vaccine treatments per patient. Patients received three to six injections i.v. of DCs pulsed with either the wild type GP2 epitope from the HER-2/neu protein or an altered peptide ligand, isoleucine to leucine (I2L). Toxicity was mild, with no patients demonstrating grade III toxicity during the treatment. Two patients with subcutaneous disease had a partial response to therapy, while IFN-γ-producing CD8+ T cells could be found in two other patients during treatment. Conclusions: This approach is safe and effective in generating a significant quantity of DCs from CD34-precursors.",
keywords = "Altered peptide ligand, Dendritic cell, HER-2/neu, Immunotherapy",
author = "Dees, {E. Claire} and McKinnon, {Karen P.} and Kuhns, {Jennifer J.} and Chwastiak, {Kathryn A.} and Scotty Sparks and Mary Myers and Collins, {Edward J.} and Frelinger, {Jeffrey A} and {Van Deventer}, Henrik and Frances Collichio and Carey, {Lisa A.} and Brecher, {Mark E.} and Mark Graham and Earp, {H. Shelton} and Serody, {Jonathan S.}",
year = "2004",
month = "9",
language = "English (US)",
volume = "53",
pages = "777--785",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "9",

}

TY - JOUR

T1 - Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer

AU - Dees, E. Claire

AU - McKinnon, Karen P.

AU - Kuhns, Jennifer J.

AU - Chwastiak, Kathryn A.

AU - Sparks, Scotty

AU - Myers, Mary

AU - Collins, Edward J.

AU - Frelinger, Jeffrey A

AU - Van Deventer, Henrik

AU - Collichio, Frances

AU - Carey, Lisa A.

AU - Brecher, Mark E.

AU - Graham, Mark

AU - Earp, H. Shelton

AU - Serody, Jonathan S.

PY - 2004/9

Y1 - 2004/9

N2 - Purpose: Immunotherapy using either dendritic cells (DCs) or expanded cytotoxic T cells (CTLs) has received increased interest in the treatment of specific malignancies including metastatic breast cancer (MBC). DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated. Methods: We enrolled ten patients with MBC that had received prior chemotherapy for the treatment of metastatic disease on a phase I/II trial designed to test the safety and feasibility of administering ex vivo expanded DCs from CD34 + progenitor cells. Results: Using a cocktail of multiple different cytokines, we could expand DCs 19-fold compared to the initial CD34-selected product, which allowed the administration of as many as six vaccine treatments per patient. Patients received three to six injections i.v. of DCs pulsed with either the wild type GP2 epitope from the HER-2/neu protein or an altered peptide ligand, isoleucine to leucine (I2L). Toxicity was mild, with no patients demonstrating grade III toxicity during the treatment. Two patients with subcutaneous disease had a partial response to therapy, while IFN-γ-producing CD8+ T cells could be found in two other patients during treatment. Conclusions: This approach is safe and effective in generating a significant quantity of DCs from CD34-precursors.

AB - Purpose: Immunotherapy using either dendritic cells (DCs) or expanded cytotoxic T cells (CTLs) has received increased interest in the treatment of specific malignancies including metastatic breast cancer (MBC). DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated. Methods: We enrolled ten patients with MBC that had received prior chemotherapy for the treatment of metastatic disease on a phase I/II trial designed to test the safety and feasibility of administering ex vivo expanded DCs from CD34 + progenitor cells. Results: Using a cocktail of multiple different cytokines, we could expand DCs 19-fold compared to the initial CD34-selected product, which allowed the administration of as many as six vaccine treatments per patient. Patients received three to six injections i.v. of DCs pulsed with either the wild type GP2 epitope from the HER-2/neu protein or an altered peptide ligand, isoleucine to leucine (I2L). Toxicity was mild, with no patients demonstrating grade III toxicity during the treatment. Two patients with subcutaneous disease had a partial response to therapy, while IFN-γ-producing CD8+ T cells could be found in two other patients during treatment. Conclusions: This approach is safe and effective in generating a significant quantity of DCs from CD34-precursors.

KW - Altered peptide ligand

KW - Dendritic cell

KW - HER-2/neu

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=4344632585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344632585&partnerID=8YFLogxK

M3 - Article

C2 - 15185007

AN - SCOPUS:4344632585

VL - 53

SP - 777

EP - 785

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 9

ER -